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Abstract
Background: Electrodermal reactivity has been successfully used as indicator of interest, curiosity as well as depressive
states. The measured reactivity depends on the quantity of sweat secreted by those eccrine sweat glands that are
located in the hypodermis of palmar and plantar regions. Electrodermal hyporeactive individuals are those who show
an unusual rapid habituation to identical non-significant stimuli. Previous findings suggested that electrodermal
hyporeactivity has a high sensitivity and a high specificity for suicide. The aims of the present study are to test the
effectiveness and the usefulness of the EDOR (ElectroDermal Orienting Reactivity) Test as a support in the suicide risk
assessment of depressed patients and to assess the predictive value of electrodermal hyporeactivity, measured through
the EDOR Test, for suicide and suicide attempt in adult patients with a primary diagnosis of depression.
Methods and design: 1573 patients with a primary diagnosis of depression, whether currently depressed or in
remission, have been recruited at 15 centres in 9 different European countries. Depressive symptomatology was
evaluated through the Montgomery-Asberg Depression Scale. Previous suicide attempts were registered and the
suicide intent of the worst attempt was rated according to the first eight items of the Beck Suicide Intent Scale. The
suicide risk was also assessed according to rules and traditions at the centre. The EDOR Test was finally performed.
During the EDOR Test, two fingers are put on gold electrodes and direct current of 0.5 V is passed through the
epidermis of the fingers according to standards. A moderately strong tone is presented through headphones now and
then during the test. The electrodermal responses to the stimuli represent an increase in the conductance due to the
increased number of filled sweat ducts that act as conductors through the electrically highly resistant epidermis. Each
patient is followed up for one year in order to assess the occurrence of intentional self-harm.
Discussion: Based on previous studies, expected results would be that patients realizing a suicide attempt with a
strong intent or committing suicide should be electrodermally hyporeactive in most cases and non-hyporeactive
patients should show only few indications of death intent or suicides.
Trial registration: The German Clinical Trials Register, DRKS00010082. Registered May 31st, 2016. Retrospectively registered.
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Background
According to the latest WHO Report [1], every year
more than 800,000 people die by suicide. Suicidal behav-
iour is one of the most common and serious psychiatric
emergency [2] and, for this reason, suicide risk assessment
is among the most important tasks of mental health
professionals.
Nevertheless, little progress has been made towards
creating effective suicide risk assessment tools. Indeed,
conventional approaches to suicide risk assessment rely
on patient self-reporting thus implying several limita-
tions concerning the possible denial of suicidal thoughts
[3, 4]. In a recent systematic review [5], no scales for
self-harm risk assessment performed sufficiently well so
as to be recommended for routine clinical use. However,
computer-based tools using implicit association tests
showed more promising results [4, 6].
Electrodermal activity (EDA) refers to changes in the
electrical conductance of the skin due to sweat gland
activity. The reactions depend on the quantity of sweat
secreted by those eccrine sweat glands that are located
in the hypodermis of palmar and plantar regions. These
glands generate sweat excreted through sweating ducts
[7]. This sympathetic nerve activity in the skin is regulated
not only by environmental temperature, but also by cen-
tral activations related to affective and cognitive states [8].
Since sweating variations are sensitive markers of events
having a particular signification for the individuals, eccrine
sweating is also known as palmar, mental or emotional
sweating [9], in opposition to the thermoregulatory
sweating. For this reason, in research, EDA has been suc-
cessfully used as indicator of emotional states, such as joy,
sadness and fear. In addition, electrodermal reactions are
evoked by information processing, such as problem solv-
ing, orienting behaviour and learning [10].
EDA comprises tonic and phasic components. Tonic
component refers to the slower acting activities and
background characteristics of the signal (skin conduct-
ance level - SCL), while the phasic component is related
to the faster changing elements of the signal, usually
associated to a stimulus (skin conductance response -
SCR) [11, 12].
The presentation of repeatedly identical non-significant
stimuli usually elicits less and less electrodermal reactions,
a phenomenon known as habituation [11] or “learning the
usual”. Electrodermally hyporeactive individuals are those
who show an unusual rapid habituation (Fig. 1). This
unusual rapid habituation is supposed to be related to
a loss of the normal emotional and information pro-
cessing reaction of interest to prosaic changes in the
environment.
Several studies reported an association between electro-
dermal hyporeactivity and suicidal tendencies, particularly
among depressed patients [13, 14].
The first observations of the relationship between elec-
trodermal hyporeactivity and suicide attempts were
made in 1986 by Edman et al. [15]. They found that vio-
lent suicide attempters and suicide completers were all
fast habituators, whereas the patients with nonviolent
methods were equally distributed between slow and fast
Fig. 1 Ideal normal habituation and electrodermal hyporeactivity in relation to the presentation of repeatedly identical non-significant stimuli
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habituation; on the contrary, suicidal ideators showed
the lowest frequency of fast habituators.
Thorell et al. [16, 17] concentrated their studies on
depressive patients reporting an extreme electrodermal
hyporesponsivity in depressed suicide attempters, but
not in non-suicidal depressed patients and healthy
controls.
A trend to a faster habituation in suicidal attempters
and completers who have used violent methods was also
confirmed by Keller et al. [18] and Wolfersdorf & Straub
[19]. Differently, Jandl et al. [20] found no difference be-
tween violent and non-violent suicide attempters, even if
suicide attempters were significantly more hyporeactive
than non-attempters.
In a meta-analysis [14] including a sample of 279 de-
pressed patients and 59 healthy subjects, electrodermal
hyporeactivity was found significantly associated to high
suicide proneness. Indeed, extremely low electrodermal
reaction showed a sensitivity of 96.6% and a specificity
of 92.9% for suicide and a sensitivity of 83.3% and raw
specificity of 92.7% for suicide and/or violent attempt,
thus indicating that electrodermal response test may have
a high discriminative validity. A further study [21, 22],
based on 783 depressive patients, treated at the Weissenau
hospital in southern Germany between 1985 and 2002,
confirmed previous results and in addition suggested that
electrodermal hyporeactivity may be a trait marker for
suicidal propensity in depression, independent from its
severity, trait anxiety, gender and age.
The neuropsychological basis of electrodermal hypor-
eactivity seems to lie in the hippocampus. It has been
hypothesized that specific neurons in the hippocampus
CA3 areas [23] prevent the natural evocation of orient-
ing attention to and curiosity in neutral events in every-
day life, which in turn prevents the cognitive and
emotional ties to everyday life events. This is thought
to lead to preparedness to leave one’s perceived incuri-
ous everyday life in face of great difficulties such as
depressive thoughts and negative attitudes [24]. Fur-
thermore, this may lead to a loss of fear of impending
fear leading to a capability to perform the action [24].
Hyporeactivity is in addition supposed to contribute to
a capability to perform the suicidal act with the
intention to die [24], due to reduced impulse regulation
(difficulty in foreseeing and avoiding strong emotional
events), in turn due to a weak input from hippocampus
to amygdala [25, 26].
It has been suggested that a suicide related previously
unknown neuropsychological dysfunction that prevents
the natural eliciting of emotional and cognitive curiosity
reactions to events in the everyday life has been detected
[27]. The dysfunction is thought to be due to specific
impairment of hippocampal functions caused by gener-
ally acting biological (e.g., stress, inflammation, genetic
influence at many levels) and specific psychological
conditions (e.g., learned helplessness, trauma) [27].
A test of ElectroDermal Orienting Reactivity (EDOR
Test) specifically optimized for the detection of electro-
dermal hyporeactivity was developed in the beginning of
1980s [16, 28]. Since then, the test has been constructed
in a way that it can be used by any member of the clin-
ical staff at the ward, after a brief training. If confirmed
the association between electrodermal hyporeactivity
and suicidal tendencies, the EDOR Test could be used as
a non-invasive suicide risk screening procedures, which
will not require technically skilled personnel or the
sophisticated instruments of a psychophysiological la-
boratory. Indeed, a previous naturalistic study proved
that a test of electrodermal hyporeactivity fits very well
into the daily clinical work [29].
Emotra AB decided to fund the EUDOR-A study,
aimed at investigating the effectiveness and the useful-
ness of the EDOR Test as an objective support in the
suicide risk assessment of patients with a primary diag-
nosis of depression in the naturalistic setting of psychi-
atric services. It is hypothesized that the EDOR Test will
identify electrodermal hyporeactive depressed patients
who in turns will show a higher suicidal proneness as
indicated by intentional self-harm behaviours.
Primary objectives of the study are:
– To study the predictive value of electrodermal
hyporeactivity measured through the EDOR Test
for intentional self-harm (i.e., suicide and suicide
attempt), with and without death intent and with
and without violent method, in adult patients
with a primary diagnosis of depression;
– To gain knowledge about influence from secondary
psychiatric diagnoses, from somatic diagnoses, age
and gender on this association;
– To study possible traces of influence on the rate of
suicide by the clinical use of the EDOR Test.
Methods/Design
Study design
EUDOR-A is a naturalistic, non-interventional study
performed at 15 different psychiatric centres in 9 differ-
ent European countries:
– Department of Emergency Psychiatry and Acute
Care, University Hospital of Montpellier,
Montpellier (France);
– Department of Psychiatry and Psychotherapy,
University of Rostock, Rostock (Germany);
– Department of Psychiatry and Psychotherapy,
University Hospital of Tuebingen, Tuebingen
(Germany);
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– III Psychiatric Department, National Institute of
Psychiatry and Addictions, Budapest (Hungary);
– Department of Medical Basic Sciences,
Neuroscience and Sense Organs, University of Bari,
Bari (Italy);
– Clinica Psichiatrica , DINOGMI, University of
Genoa, Genoa (Italy);
– Psychiatry Institute, Department of Translational
Medicine, University of Eastern Piedmont; S.C.
Psichiatria, AOU Maggiore della Carità, Novara
(Italy);
– Department of Psychiatry, Medical University of
Warsaw, Warsaw (Poland);
– 2nd Psychiatric Department, Institute of Psychiatry
and Neurology, Warsaw (Poland);
– Centro Hospitalar de Lisboa Ocidental (CHLO),
Lisbon (Portugal);
– Clinical Psychology and Mental Health Department,
Iuliu Hatieganu University of Medicine and
Pharmacy, Cluj-Napoca (Romania);
– Department of Psychiatry, University of Oviedo
CIBERSAM, Oviedo (Spain);
– Department of Psychiatry, Fundacion Jimenez Diaz
University Hospital, Autonomous University of
Madrid, Madrid (Spain);
– Psychiatric Neuromodulation Unit, Department of
Clinical Sciences, Faculty of Medicine, Lund
University, Lund (Sweden);
– Psychiatric Neuromodulation Unit (PNU), Department
of Clinical Neurosciences, Malmö University Hospital,
Malmö (Sweden).
EUDOR-A received the ethical approval at each study
site and it was registered in the German Clinical Trials
Register (DRKS00010082).
The study planned to recruit at least 1500 patients
with a primary diagnosis of depression, also in remission,
between August, 2014 and March, 2016. After obtaining
the informed consent, a clinical assessment, also including
information on the severity of depression and previous ac-
tions of intentional self-harm, has been performed. Finally,
the patients underwent the EDOR Test to assess their
level of electrodermal reactivity. The suicide risk assess-
ment, made during the clinical assessment, could also be
revised based on the results of the EDOR Test. Each
patient is followed up for one year in order to assess
the actions of intentional self-harm occurred in this
period.
In the current observational study, the primary variables
to be investigated are:
– the prevalence of electrodermal hyporeactivity
among depressive patients recruited and tested in
the naturalistic setting of psychiatric clinics;
– the incidence of actions of intentional self-harm (i.e.,
suicide attempt/s before the EDOR Test and during
the one-year follow-up period and suicide during the
one-year follow-up period).
Secondary outcomes to be assessed are:
– the influence of secondary psychiatric diagnoses,
antidepressant treatments, somatic diagnoses, as
well as demographic characteristics, such as age and
gender, on electrodermal reactivity levels;
– possible traces of influence on the rate of suicide by
the clinical use of the EDOR Test.
Sample size calculation
In order to reach a power of 80% with an alpha level of
0.05 on the Chi-Square test, it has been calculated that
at least 47 patients with intentional self-harm (i.e., sui-
cide and suicide attempt) and at least 187 patients with-
out intentional self-harm are required. Increasing the
power to 95% at least 78 patients with intentional self-
harm (i.e., suicide and suicide attempt) and at least 311
patients without intentional self-harm are required. The
study sample potentially exceeds the sample size require-
ments in order to detect statistically significant changes.
This will ensure the required statistical power, taking
into account the possibility of some center recruiting
fewer pupils than expected, attrition rates at follow-up
and missing data.
Study participants
In- and out-patients with a primary diagnosis of depres-
sion, also in remission, have been recruited.
The complete list of allowed primary psychiatric ICD-
10 (International Statistical Classification of Diseases
and Related Health Problems 10th Revision) [30] diag-
noses is showed in Table 1.
Patients were eligible to participate only if all the
following inclusion criteria were met:
– Primary diagnosis of depression according to the
ICD-10, also in remission;
– Age: 18 years or older;
– Gender: Any;
– Signed Informed Consent.
Patients were excluded in case of:
– Dissent to participate in the study;
– Inability to understand the instructions for the
EDOR Test;
– Serious problems of hearing.
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In cases of diagnosed or suspected dementia or known
or suspected alcohol or other substance abuse, the
patient was excluded unless there was a special interest
by the centre. If included, these conditions were specific-
ally noted.
Measurements
A comprehensive clinical assessment form has been used
in order to collect information concerning socio-
demographic characteristics of the subjects, primary and
secondary psychiatric and somatic diagnoses, pharmaco-
logical and psychological treatment.
Depressive symptomatology has been evaluated through
the Montgomery-Asberg Depression Rating Scale [31, 32].
The scale comprises ten items on a 7-point Likert scale
(0-6), with higher scores reflecting more severe symptoms
of depression. The scale was developed to measure the
severity of depressive episodes in patients with mood dis-
orders and explores the following symptoms: apparent
sadness, reported sadness, inner tension, reduced sleep,
reduced appetite, concentration difficulties, lassitude, in-
ability to feel, pessimistic thoughts and suicidal thoughts.
For the purpose of this study, suicide has been defined
as an act that is judged to have been deliberately initi-
ated and performed in the full knowledge or expectation
of its fatal outcome [33]. While a suicide attempt repre-
sents any action of intentional self-harm with at least
some intent to die [33].
Information regarding number, time and method
(ICD-10 codes) of previous suicide attempts has been
collected. The death intent of the worst attempt con-
cerning death intent, according to the patient, was rated
using the first eight items of the Beck Suicide Intent
Scale [34]. The original scale is a semi-structured inter-
view including 15 items on a 3-point Likert scale (0-2)
assessing the severity of suicide attempts. For the pur-
pose of this study, only the first eight items were used
exploring the following characteristics of the suicide at-
tempt: isolation, timing, precautions against discovery/
intervention, acting to get help during/after attempt,
final acts in anticipation of death, active preparation for
attempt, suicide note and overt communication of in-
tent before the attempt. The value of this short version
of the Beck Suicide Intent Scale has been previously
explored [35, 36].
For each patient, the suicide risk has also been assessed,
according to rules and traditions at the centre, and rated
on a 5-point scale, form 0 - none to 4 - very high.
After the clinical assessment, the EDOR (ElectroDer-
mal Orienting Reactivity) Test was finally performed by
a trained member of the clinical staff (Fig. 2). The EDOR
Test is developed by the Swedish company Emotra AB.
The test is non-invasive and takes about 15 minutes.
During the EDOR Test, two fingers of the non-
dominant hand are put on two gold electrodes and a dir-
ect current of 0.5 V is passed through the epidermis of
the fingers according to standards. A moderately strong
tone (1s, 90 dB, 1kHz) is presented through headphones
in intervals ranging from 20s – 80s during the test. Sen-
sors located within the electrodes are able to register the
Table 1 List of allowed primary psychiatric ICD-10 diagnoses
F31 Bipolar affective
disorder
F31.3 Bipolar affective disorder, current episode
mild or moderate depression
F31.4 Bipolar affective disorder, current episode
severe depression without psychotic symptoms
F31.5 Bipolar affective disorder, current
episode severe depression with psychotic
symptoms
F31.6 Bipolar affective disorder, current
episode mixed
F31.7 Bipolar affective disorder, currently
in remission
F31.8 Other bipolar affective disorders
F31.9 Bipolar affective disorder, unspecified
F32 Depressive episode F32.0 Mild depressive episode
F32.1 Moderate depressive episode
F32.2 Severe depressive episode without
psychotic symptoms
F32.3 Severe depressive episode with
psychotic symptoms
F32.8 Other depressive episodes
F32.9 Depressive episode, unspecified
F33 Recurrent depressive
disorder
F33 Recurrent depressive disorder
F33.1 Recurrent depressive disorder, current
episode moderate
F33.2 Recurrent depressive disorder, current
episode severe without psychotic symptoms
F33.3 Recurrent depressive disorder, current
episode severe with psychotic symptoms
F33.4 Recurrent depressive disorder, currently
in remission
F33.8 Other recurrent depressive disorders
F33.9 Recurrent depressive disorder,
unspecified
F34 Persistent mood
[affective] disorders
F34.0 Cyclothymia
F34.1 Dysthymia
F34.8 Other persistent mood [affective]
disorders
F34.9 Persistent mood [affective] disorder,
unspecified
F38 Other mood
[affective] disorders
F38.0 Other single mood [affective] disorders
F38.1 Other recurrent mood [affective]
disorders
F38.8 Other specified mood [affective]
disorders
F39 Unspecified mood [affective] disorder
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electrodermal response to those tones, measuring the
skin conductance. The electrodermal responses to the
stimuli represent an increase in the conductance due to
the increased number of filled sweat ducts that act as
conductors through the electrically highly resistant epi-
dermis. Sensors are also able to register blood volume
variation.
The EDOR Test is connected via Bluetooth with a
computer and the skin conductance signal and the blood
volume appear on the screen. Through the events buttons,
the test leader can mark certain events having potential
significance for the interpretation of the physiological
signals (e.g., sneezing, body movements, etc.).
Once the test is finished, data are sent anonymously
over the Internet for remote expert analyses at Emotra.
Persons who analyse test data are blind to the assessment
of clinical data.
Finally, a Test Report is sent by Emotra back to the
predefined authorized e-mail of the centre. The test
report contains information on the quality of the assess-
ment and the categorization into Hyporeactivity, On the
verge of hyporeactivity, Reactivity and Hyperactivity.
Since hyporeactivity was previously found to correlate
with suicidal risk [14, 21], based on the results of elec-
trodermal response tests, the clinicians could possible
revise the suicide risk assessment.
Each patient is followed up for one year. During the
follow-up assessment, data on the number of depressive
episodes and actions of intentional self-harm occurred
in this period are collected. In particular, information
regarding the number of suicide attempts, the method/s
used according ICD-10 codes, and if these actions
resulted in a suicide is collected. The first eight items of
the Beck Suicide Intent Scale are used to evaluate the
severity of the death intent in the eventual suicide or
worst suicide attempt, according to the patient.
Statistical analysis
The statistical analyses applied are the computation of the
prevalence of Hyporeactivity in the whole and subgroups
of the patients, for example socio-economic classifica-
tions, groups of diagnoses and medical treatment. This is
valid also for the computations of sensitivity and raw spe-
cificity (negative predictive value) to types of suicidal
behaviours, except for suicide, which has been applied and
explained before [17a 17b], which also are computed on
the whole material and subgroups. Only non-parametric
tests are applied.
Ethical considerations
The study protocol received the ethical approval from
the competent Ethical Committee in each participating
centre where the research project has been implemented.
Beside the explanations from their clinicians, the par-
ticipants received an informational sheet. The partici-
pants were informed that the EDOR Test is studied as a
new tool for helping doctors in assessing the risk of sui-
cide in depressed patients. They were also informed that
the results of the test would be interpreted by an inter-
national expert and then transmitted to their doctors.
A signed Informed Consent was obtained for each
recruited patient.
Fig. 2 The EDOR (ElectroDermal Orienting Reactivity) Test
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In order to ensure confidentiality, a specific code was
assigned to each participant and has been used instead
of the name in the baseline and follow-up assessments.
Because of the strong evidence today to the favour of
tests of electrodermal hyporeactivity in detecting depres-
sive patients with suicidal propensity, it was considered
unethical to do a blind study with a control group whose
test results were ignored in the clinical assessment of
suicide risk. Therefore, each centre was free and strongly
encouraged to use the results from the EDOR Test in
their clinical suicide risk assessments and planning of
the care of the participating patients.
Discussion
Several studies have reported data showing a strong
association between electrodermal hyporeactivity and
suicidal behaviour in depressed patients [14, 21]. The
findings have promoted the development of the EDOR
Test by Emotra AB, Sweden. The test is optimized for
detecting hyporeactivity and for routine use by specific-
ally trained staff members of psychiatric clinics.
It is hypothesized that the EDOR Test will identify
electrodermal hyporeactive depressed patients who in
turns will show a higher suicidal proneness as indicated
by intentional self-harm behaviours. Patients that in a
suicide attempt reveals strong death intent should be
electrodermally hyporeactive in most cases and non-
hyporeactive patients should show only few indications
of death intent.
It is expected that the test of electrodermal hyporeac-
tivity detects a previously unknown neuropsychological
dysfunction that is independent of the depressive state
and can be useful in the assessment of suicidality with a
high sensitivity and specificity.
The estimated cost for the EDOR equipment is 5500€
and the cost for each analysis 100€. A preliminary eco-
nomic feasibility study has been performed in the region
Östergötland of Sweden (unpublished data). It has been
estimated that testing all depressed patients in the region
would procure savings for healthcare of 16 million € for
a 50% reduction in the number of suicide attempts and
25 million Euro for a 75% reduction in suicide attempts.
This estimation does not take into account savings
related to suicide preventive strategies for patients with
no risk nor the social and psychological costs related to
suicide survivors.”
EUDOR-A presents several strengths. It is the first
study evaluating the effectiveness and the usefulness of
an objective and non-invasive tool (the EDOR Test) in
order to be used as support in the suicide risk assess-
ment of depressed patients. Moreover, EUDOR-A is con-
ducted in the naturalistic setting of psychiatric services,
so allowing a more easy translation of research findings
into the clinical practice. All the members of the staff
involved in the research were specifically trained on the
use of the EDOR Test, as well as on the collection of
clinical information, in order to maximise the reliability
and validity of gathered data.
The main limitations of the study rely in the fact that
many of the suicide-related information are self-reported.
However, the participating centres were strongly encour-
aged to gather the access also to medical records. More-
over, for ethical reasons it was not possible to conduct a
blind study in which EDOR test results were ignored in
the clinical assessment of suicide risk. The consequent
implementation of suicide preventive interventions and
treatments for those patients considered at risk may influ-
ence the incidence of suicide attempts in the one-year
follow-up period, thus possibly reducing the association
between hyporeactivity and suicide proneness.
In conclusion, EUDOR-A is expected to provide scien-
tific evidence for understanding the link between hypor-
eactivity, as measured by the EDOR Test, and suicidal
behaviour in depressed patients, also investigating po-
tential influences exerted by other variables such as sec-
ondary psychiatric diagnoses, antidepressant treatments,
somatic diagnoses, age and gender. The results of the
present study may validate the use of the EDOR Test as
an objective and non-invasive tool in the suicide risk
assessment of depressed patients.
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